Skip to content
MarketScale
‹ Back to IndustriesSciences

Denali Water Solutions, LLC Acquires Stock of Veris Environmental, LLC and AWS Dredge, LLC

Russellville, Arkansas – October 26, 2020 – Denali Water Solutions, LLC announced that it has acquired the stock of Veris Environmental, LLC and AWS Dredge, LLC. Veris Environmental, LLC is a residuals management services company providing biosolids recycling and transportation, dewatering, digester cleaning, lagoon services and sediment removal, and land application services in the western…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · Aws DredgeDenaliJay HolmesLiquid Waste Management
Share
Denali Water Solutions, LLC Acquires Stock of Veris Environmental, LLC and AWS Dredge, LLC

Key takeaways

01

Russellville, Arkansas – October 26, 2020 – Denali Water Solutions, LLC announced that it has acquired the stock of Veris Environmental, LLC and AWS Dredge, LLC.

02

Veris Environmental, LLC is a residuals management services company providing biosolids recycling and transportation, dewatering, digester cleaning, lagoon services and sediment removal, and land application services in the western…

Russellville, Arkansas – October 26, 2020 – Denali Water Solutions, LLC announced that it has acquired the stock of Veris Environmental, LLC and AWS Dredge, LLC. Veris Environmental, LLC is a residuals management services company providing biosolids recycling and transportation, dewatering, digester cleaning, lagoon services and sediment removal, and land application services in the western United States. AWS Dredge, LLC, is a service provider to hard rock mines in the western United States. The stock purchase aligns with Denali’s strategic growth plan of expansion to additional markets and geographical regions.

“We are thrilled to welcome the Veris Environmental and AWS Dredge teams to the Denali family. This decision aligns with our goal of building a team with strong and experienced leaders to enhance our safety-focused and quality residuals management services to our customers and to the communities we live and work in,” noted Andy McNeill, CEO of Denali Water Solutions.

Kipp Parker, the majority owner of Veris Environmental and founder of Parker Ag Services, stated that he is grateful to have formed a relationship with Denali Water Solutions and is looking forward to seeing the expansion of the stewardship of the company he has built over the years.

Jay Holmes, CEO of Veris Environmental and founder of Liquid Waste Management, and Mike Scharp, Vice President of Marketing and Technical Services of Veris Environmental and a long term partner in Parker Ag Services, have both expressed excitement about joining the Denali Water Solutions leadership team as Denali expands their market area into the Rocky Mountain region of the United States.

About Denali Water Solutions

Denali Water Solutions is a specialty waste and environmental services company that believes it is the collective responsibility of us all to protect the quality of water and natural resources through recycling waste in sustainable ways, can be beneficially reused, and reduce or eliminate the use of landfills. Our vision is to meet this responsibility by offering innovative and economically effective solutions for the management, handling, recycling, disposal, and conversion of organic waste materials through beneficial reuse, composting, and anaerobic digestion for the customers and communities we serve. Denali Water Solutions is a full-service provider throughout the organic waste management cycle; processed waste is dewatered then recycled through liquid and solid land applications, chemical treatment, and composting. Beneficial use and recycling methods create sustainability benefits through fertilizing farmland, enhancing soil health with compost, and generating clean water. To learn more, please visit here.

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences